Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 34Lymphoma, Non-Hodgkin 31Lymphoma 20Lymphoma, Mantle-Cell 18Multiple Myeloma 17Lymphoma, Follicular 16Lymphoma, Large B-Cell, Diffuse 14Hodgkin Disease 11Lymphoma, B-Cell, Marginal Zone 9Recurrence 6Leukemia 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Waldenstrom Macroglobulinemia 4Neoplasms, Plasma Cell 4Lymphoma, B-Cell 3Leukemia, Lymphoid 3Hematologic Diseases 3Burkitt Lymphoma 3Small Cell Lung Carcinoma 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Mycosis Fungoides 2Lymphoma, T-Cell, Peripheral 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Extranodal NK-T-Cell 2Leukemia, Hairy Cell 2

Interventions

rasburicase 3Allopurinol 3Febuxostat 2venetoclax 1obinutuzumab 1alvocidib 1Urate Oxidase 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Tumor Lysis Syndrome × Bendamustine Hydrochloride × Clear all
NCT03406156 2024-08-06

A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

AbbVie

Phase 3 Completed
120 enrolled 14 charts
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Neoplasms, Tumor Lysis Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡